Alternative Analyses Clause Samples

Alternative Analyses. This section briefly considers the most prominent alternative analyses, demonstrating that an analysis of the null logophoric operator as a subject-oriented anaphor achieves much better empirical coverage than the alternatives. In the course of the discussion, I discuss how the empirical predictions of these analytical alternatives for the subject- operator relationship do in fact occur cross-linguistically, demonstrating not only that there is rich typological variation in the nature of logphoric operators, but also defending the claim that the Lubukusu case at its core is an anaphoric relationship.
View Source
Alternative Analyses. We believe that any design alternative or a combination of alternatives should consider repairing the failed portion of the low-flow channel to which the 60-inch pipe daylights and discharges into. If not address, there is a potential for further erosion of the low-flow channel at the outfall which may eventually result in an unstable slope. BKF will evaluate up to two alternatives to replace and/or repair the existing improvements within the low-flow channel and at the pipe discharge location. The alternatives will focus improvements required to reduce exit velocities and dissipation of energy to prevent further undermining. Evaluation of alternatives will take into account method of installation, required permits, right-of-way requirements, duration and sequence of construction, constructability, cost and schedule. The design life of CMP pipes is generally 50-years but can be extended by lining the pipe which is the case hear. The 60-inch asphalt lined CMP pipe is showing signs of wear and tear and this presents a great opportunity to rehabilitate the CMP pipe as any future repairs to the pipe will again trigger permits with regulatory agencies. As part of this scope, BKF will evaluate the best CMP rehabilitation method. Alternatives will be limited to rehabilitation methods such as cure-in- place pipe lining, slip-lining or shortcrete lining. BKF will prepare schematic drawings showing existing topographic data, utilities and proposed improvement alternatives.
View Source

Related to Alternative Analyses

  • Investment Analysis and Implementation In carrying out its obligations under Section 1 hereof, the Advisor shall: (a) supervise all aspects of the operations of the Funds; (b) obtain and evaluate pertinent information about significant developments and economic, statistical and financial data, domestic, foreign or otherwise, whether affecting the economy generally or the Funds, and whether concerning the individual issuers whose securities are included in the assets of the Funds or the activities in which such issuers engage, or with respect to securities which the Advisor considers desirable for inclusion in the Funds' assets; (c) determine which issuers and securities shall be represented in the Funds' investment portfolios and regularly report thereon to the Board of Trustees; (d) formulate and implement continuing programs for the purchases and sales of the securities of such issuers and regularly report thereon to the Board of Trustees; and (e) take, on behalf of the Trust and the Funds, all actions which appear to the Trust and the Funds necessary to carry into effect such purchase and sale programs and supervisory functions as aforesaid, including but not limited to the placing of orders for the purchase and sale of securities for the Funds.

  • Quantitative Analysis Quantitative analysts develop and apply financial models designed to enable equity portfolio managers and fundamental analysts to screen potential and current investments, assess relative risk and enhance performance relative to benchmarks and peers. To the extent that such services are to be provided with respect to any Account which is a registered investment company, Categories 3, 4 and 5 above shall be treated as “investment advisory services” for purposes of Section 5(b) of the Agreement.”

  • Special Analyses It is hereby certified that these regulations will not have a significant economic impact on a substantial number of small entities. This certification is based on the fact that it is unlikely that a substantial number of small entities will hold REMIC residual interests. Therefore, a Regulatory Flexibility Analysis under the Regulatory Flexibility Act (5 U.S.C. chapter 6) is not required. It has been determined that this Treasury decision is not a significant regulatory action as defined in Executive Order 12866. Therefore, a regulatory assessment is not required. It also has been determined that sections 553(b) and 553(d) of the Administrative Procedure Act (5 U.S.C. chapter 5) do not apply to these regulations. The principal author of these regulations is ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇. However, other personnel from the IRS and Treasury Department participated in their development. 26 CFR Part 1 Income taxes, Reporting and record keeping requirements.

  • Investment Analysis and Commentary The Subadviser will provide quarterly performance analysis and market commentary (the “Investment Report”) during the term of this Agreement. The Investment Reports are due within 10 days after the end of each quarter. In addition, interim Investment Reports shall be issued at such times as may be mutually agreed upon by the Adviser and Subadviser; provided however, that any such interim Investment Report will be due within 10 days of the end of the month in which such agreement is reached between the Adviser and Subadviser. The subject of each Investment Report shall be mutually agreed upon. The Adviser is freely able to publicly distribute the Investment Report.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.